Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 16/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074451 | 0.90 | DRD4 (0.41) | SIGMAR1DRD4CCR2KCNH2ROCK2 | |
| SCHEMBL1119775 | 0.88 | CCR2 (0.41) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1119323 | 0.87 | CCR2 (0.44) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1120051 | 0.85 | CCR2 (0.41) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1119340 | 0.85 | CCR2 (0.40) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1119856 | 0.84 | CCR2 (0.43) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL3735950 | 0.84 | CCR2 (0.42) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL3742106 | 0.84 | CCR2 (0.42) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1119890 | 0.84 | CCR2 (0.42) | SIGMAR1CCR2KCNH2CCR1TMEM97 | |
| SCHEMBL1119354 | 0.83 | CCR2 (0.41) | SIGMAR1CCR2KCNH2CCR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280766-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | CytoPathfinder, Inc. (JP) | 2011-02-09 | — | — | EP | claimed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | claimed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | claimed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2280766-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | CytoPathfinder, Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| WO-2010129843-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | CYTOPATHFINDER, INC. (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129843-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | CYTOPATHFINDER, INC. (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076512-A1 | CARBOXAMIDΞ COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | ALDH1A2, QDPR, PDE6C | SIGMAR1 2778/4885DRD4 42/4885CCR2 3022/4885 |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | SIGMAR1 390/4885DRD4 2574/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.